Xenograft Model Antitumor Assays

"Xenograft Model Antitumor Assays" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.

Descriptor ID	D023041
MeSH Number(s)	E05.337.550.200.900 E05.624.850
Concept/Terms	Xenograft Model Antitumor Assays Xenograft Model Antitumor Assays Tumor Xenograft Assay Xenograft Antitumor Assays Antitumor Assay, Xenograft Antitumor Assays, Xenograft Assay, Xenograft Antitumor Assays, Xenograft Antitumor Xenograft Antitumor Assay Antitumor Assays, Xenograft Model

Below are MeSH descriptors whose meaning is more general than "Xenograft Model Antitumor Assays".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Evaluation Studies as Topic [E05.337]
Drug Evaluation, Preclinical [E05.337.550]
Drug Screening Assays, Antitumor [E05.337.550.200]
Xenograft Model Antitumor Assays [E05.337.550.200.900]
Neoplasm Transplantation [E05.624]
Xenograft Model Antitumor Assays [E05.624.850]

Below are MeSH descriptors whose meaning is related to "Xenograft Model Antitumor Assays".

Below are MeSH descriptors whose meaning is more specific than "Xenograft Model Antitumor Assays".

Xenograft Model Antitumor Assays
Subrenal Capsule Assay

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Xenograft Model Antitumor Assays" by people in this website by year, and whether "Xenograft Model Antitumor Assays" was a major or minor topic of these publications.

Bar chart showing 164 publications over 23 distinct years, with a maximum of 18 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	0	4	4
2004	0	1	1
2005	1	2	3
2006	0	3	3
2007	0	3	3
2008	0	4	4
2009	0	4	4
2010	1	12	13
2011	1	8	9
2012	1	4	5
2013	0	8	8
2014	0	10	10
2015	1	11	12
2016	1	12	13
2017	0	18	18
2018	0	16	16
2019	1	9	10
2020	0	3	3
2021	0	8	8
2022	0	1	1
2024	2	4	6
2025	0	6	6
2026	0	4	4

Below are the most recent publications written about "Xenograft Model Antitumor Assays" by people in Profiles.

Jamroze A, Liu X, Hou S, Jess Li W, Yu H, Tracz A, Jacobi J, Li Q, Nastiuk K, Chen X, Huang J, Lin K, Liu M, Cai C, Lu Y, Puzanov I, Kirk JS, Chatta G, Tang DG. Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer. Signal Transduct Target Ther. 2026 May 01; 11(1).

View in: PubMed
Cui W, Xiao H, Wen X, Li C, Bao S, Zeng J, Li Y, Qiao Y, Wang K, Wang H, Huang J, Guo Q. Identifying a cancer therapeutic target: Cell-SELEX identifies a membrane protein for aptamer-mediated growth suppression. Proc Natl Acad Sci U S A. 2026 Mar 31; 123(13):e2514681123.

View in: PubMed
Yu JX, Suh JM, Popova KD, Garcia K, Joshi T, Culbertson B, Spinelli JB, Subramanyam V, Lou K, Charbonneau T, Shokat KM, Weissman J, Goodarzi H. The GENEVA platform models tumor mosaicism to reveal variations of responses to KRAS inhibitors and identify improved drug combinations. Nat Cancer. 2026 Mar; 7(3):522-537.

View in: PubMed
Itoh-Nakadai A, Liang M, Shindo M, Bibi C, Tomizawa-Murasawa M, Fujiki S, Kaneko A, Kanamaru E, Hashimoto M, Kajita H, Ando Y, Kojima M, Moody J, Iwasaki M, Takagi S, Nakagawa R, Agrawal S, Amitani-Iijima H, Sato K, Sorimachi Y, Suzuki N, Fukami T, Hanada K, Morita S, Katsura K, Matsumoto T, Kobayashi M, Kato M, Negishi Y, Shirouzu M, Najima Y, Takubo K, Hon CC, Uchida N, Taniguchi S, Momozawa Y, Carninci P, Shultz LD, Saito Y, de Hoon M, Shin JW, Ishikawa F. CXCR4 induces memory formation over exhaustion in CAR-T cells to achieve durable leukemia targeting. Nat Commun. 2026 Jan 26; 17(1):101.

View in: PubMed
Kim J, Shin DW, Lee J, Lee MJ, Yu YG, Lee DH, Kang TH. Engineering Native-like GPCR Antigens Enables Discovery of an LPA2-Blocking Antibody for Ovarian Cancer. ACS Synth Biol. 2026 01 16; 15(1):309-320.

View in: PubMed
Qiu J, Alp Y, Gong S, Szipszky P, Jerry DJ, Thayumanavan S. HER2 Antibody-Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody-Drug Conjugates. Nano Lett. 2026 01 14; 26(1):246-253.

View in: PubMed
Giovannoni F, Strathdee CA, Faust Akl C, Andersen BM, Li Z, Lee HG, Torti MF, Rone JM, Duart-Abadia P, Molgora M, Kong L, Floyd M, Teng J, Gyulakian Y, Grzesik P, Farkaly T, Denslow A, Feau S, Rodriguez-Sanchez I, Jacques J, Colonna M, Kennedy EM, Cheema T, Lerner L, Qu?va C, Quintana FJ. Retargeted oncolytic viruses engineered to remodel the tumor microenvironment for glioblastoma immunotherapy. Nat Cancer. 2025 Dec; 6(12):1994-2010.

View in: PubMed
Labaf M, Han W, Zhang S, Liu M, Patten ND, Li M, Patalano S, Macoska JA, Balk SP, Han D, Zarringhalam K, Cai C. Heterogeneous Responses to High-Dose Testosterone in Castration-Resistant Prostate Cancer Tumors with Mixed Rb-Proficient and Rb-Deficient Cells. Mol Cancer Ther. 2025 May 02; 24(5):772-783.

View in: PubMed
Kosti P, Abram-Saliba J, Pericou-Troquier L, Pavelot S, Ruggeri T, Laffaille M, Irving M, Coukos G, Lanitis E, Dunn SM. Potent and durable control of mesothelin-expressing tumors by a novel T cell-secreted bi-specific engager. J Immunother Cancer. 2025 Mar 13; 13(3).

View in: PubMed
Banday S, Mishra AK, Rashid R, Ye T, Ali A, Li J, Yustein JT, Kelliher MA, Zhu LJ, Deibler SK, Malonia SK, Green MR. The O-glycosyltransferase C1GALT1 promotes EWSR1::FLI1 expression and is a therapeutic target for Ewing sarcoma. Nat Commun. 2025 Feb 02; 16(1):1267.

View in: PubMed

People

Explore

Similar Concepts

Top Journals